Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,542 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease.
Sandborn WJ, Bhandari BR, Randall C, Younes ZH, Romanczyk T, Xin Y, Wendt E, Chai H, McKevitt M, Zhao S, Sundy JS, Keshav S, Danese S. Sandborn WJ, et al. Among authors: xin y. J Crohns Colitis. 2018 Aug 29;12(9):1021-1029. doi: 10.1093/ecco-jcc/jjy049. J Crohns Colitis. 2018. PMID: 29767728 Free PMC article. Clinical Trial.
Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis.
Sandborn WJ, Bhandari BR, Fogel R, Onken J, Yen E, Zhao X, Jiang Z, Ge D, Xin Y, Ye Z, French D, Silverman JA, Kanwar B, Subramanian GM, McHutchison JG, Lee SD, Shackelton LM, Pai RK, Levesque BG, Feagan BG. Sandborn WJ, et al. Among authors: xin y. Aliment Pharmacol Ther. 2016 Jul;44(2):157-69. doi: 10.1111/apt.13653. Epub 2016 May 24. Aliment Pharmacol Ther. 2016. PMID: 27218676 Free PMC article. Clinical Trial.
Phase 1 First-in-Human, Single- and Multiple-Ascending Dose, and Food Effect Studies to Assess the Safety, Tolerability, and Pharmacokinetics of Presatovir for the Treatment of Respiratory Syncytial Virus Infection.
German P, Xin Y, Chien JW, Weng W, Mackman R, Lewis SA, Meng A, Ling J, Mathias A. German P, et al. Among authors: xin y. J Clin Pharmacol. 2018 Aug;58(8):1025-1034. doi: 10.1002/jcph.1112. Epub 2018 Apr 17. J Clin Pharmacol. 2018. PMID: 29663420
Oral GS-5806 activity in a respiratory syncytial virus challenge study.
DeVincenzo JP, Whitley RJ, Mackman RL, Scaglioni-Weinlich C, Harrison L, Farrell E, McBride S, Lambkin-Williams R, Jordan R, Xin Y, Ramanathan S, O'Riordan T, Lewis SA, Li X, Toback SL, Lin SL, Chien JW. DeVincenzo JP, et al. Among authors: xin y. N Engl J Med. 2014 Aug 21;371(8):711-22. doi: 10.1056/NEJMoa1401184. N Engl J Med. 2014. PMID: 25140957 Free article. Clinical Trial.
The Drug-Drug Interaction Profile of Presatovir.
Xin Y, Weng W, Murray BP, Eisenberg EJ, Chien JW, Ling J, Silverman JA. Xin Y, et al. J Clin Pharmacol. 2018 Jun;58(6):771-780. doi: 10.1002/jcph.1073. Epub 2018 Feb 7. J Clin Pharmacol. 2018. PMID: 29412463 Clinical Trial.
3,542 results